Andalucia pioneers free access to life-changing gene therapy for rare skin disorder

Andalucia has become the first Spanish region to offer Vyjuvek through its public health system. The groundbreaking treatment targets dystrophic epidermolysis bullosa, a rare genetic disorder causing severe skin fragility. Patients and campaigners have long pushed for access to the costly therapy, which can exceed €100,000 per month. Dystrophic epidermolysis bullosa leaves sufferers with skin so delicate that even minor contact causes painful blisters and wounds. Adrian, one of those affected, has endured repeated surgeries and daily wound care for years. Another patient, Leo, recently received his first Vyjuvek dose, describing himself as nervous but prepared for the treatment.

The drug works by delivering a functional copy of the faulty gene directly to skin cells. It marks the first approved therapy specifically designed for this condition. Around 45 people in Andalucia now qualify for the treatment, fully funded by the regional health service. Campaign group DEBRA Piel de Mariposa has fought tirelessly for Vyjuvek’s inclusion in Spain’s public health provision. Director Evanina Morcillo welcomed the first regional approvals but stressed the need for nationwide coverage. Earlier this year, two families—including Leo’s—took their plea for access to the European Parliament, highlighting the urgent demand for solutions. With lifetime treatment costs running into millions per patient, the decision to fund Vyjuvek represents a significant commitment by Andalucia’s health authorities.

The regional approval brings hope to patients who previously had no treatment options. Andalucia’s move sets a precedent for other Spanish regions considering similar steps. For now, those eligible can access Vyjuvek without personal cost, though broader national inclusion remains the next goal.